Abstract
Purpose
This study evaluated the risk factors associated with recurrence OM-89 (Uro-Vaxom®) treatment for female recurrent cystitis.
Materials and Methods
The medical records of patients who received OM-89 for at least six months were reviewed retrospectively. Patients were excluded from the analysis if they had an abnormal lower urinary tract anatomy, residual urine volume ≥200 ml, a history of genitourinary tuberculosis, urological cancer or pelvic radiation, indwelling urinary catheter, or had genitourinary surgery within the previous six months. Patients were categorized into two groups: (1) no recurrence and (2) recurrent cystitis after OM-89. The risk factors in the two groups were compared. The recurrent cystitis was defined as two more infections in six months or three or more in one year.
Results
A total of 52 female were included. Group 1 had 35 (67.3%) patients and group 2 had 17 (32.7%) patients. Before and after the OM-89, the mean cystitis episodes for six months of groups 1 and 2 were 4.19±4.60 (range, 2–24) and 1.17±1.79 (range, 0–6), respectively, which were decreased significantly (p <0.001). For recurrence after the OM-89, the only risk factor was uncontrolled diabetes (fasting plasma glucose level >120 mg/dl±casual plasma glucose >180 mg/dl) (p=0.002). No significant differences in the age, menopause, daily water intake, hormone replacement therapy or history of extended-spectrum beta-lactamase-producing Escherichia coli were observed between the two groups.
References
1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002; 113(Suppl 1A)::5–13S.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
2. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health. 1990; 80:331–3.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
3. Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000; 182:1177–82.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
4. Albert X, Huertas I, Pereiro II, Sanfelix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in nonpregnant women. Cochrane Database Syst Rev. 2004. CD001209.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
5. Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and metaanalysis of randomized controlled trials. J Urol. 2013; 190:1981–9.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
6. Naber KG, Cho YH, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a metaanalysis. Int J Antimicrob Agents. 2009; 33:111–9.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
7. Stamm WE, McKevitt M, Roberts PL, White NJ. Natural history of recurrent urinary tract infections in women. Rev Infect Dis. 1991; 13:77–84.
8. Schmidhammer S, Ramoner R, Holtl L, Bartsch G, Thurnher M, Zelle-Rieser C. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology. 2002; 60:521–6.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
9. Lee SJ, Kim SJ, Cho YH, Woo YN, Kim BW, Chang SG, et al. Efficacy and safety of Uro-vaxom treatment for patients with recurrent cystitis: an open multicenter study. Korean J Urol. 2007; 48:428–32.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
10. Geerlings SE, Brouwer EC, Gaastra W, Verhoef J, Hoepelman AI. Effect of glucose and pH on uropathogenic and non-uro-pathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. J Med Microbiol. 1999; 48:535–9.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
11. Geerlings SE, Meiland R, van Lith EC, Brouwer EC, Gaastra W, Hoepelman AI. Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells: more in diabetic women than in control subjects. Diabetes Care. 2002; 25:1405–9.
Table 1.
Patients' baseline characteristics (n=52)
Table 2.
Clinical characterisrics of the patients with recurrent cystitis after OM-89 treatment